Basics Insmed, Inc. Insmed Inc is a global biotechnology company. It is focused on developing novel therapies that focus primarily on lung diseases. IPO Date: June 1, 2000 Sector: Healthcare Industry: Biotech Market Cap: $30.67B Activated in VL: True Average Daily Range Avg Daily Range: $0.41 | 2.83% Avg Daily Range (30 D): $1.87 | 1.56% Avg Daily Range (90 D): $1.52 | 1.59% Institutional Daily Volume Avg Daily Volume: .8M Avg Daily Volume (30 D): 2.49M Avg Daily Volume (90 D): 2.66M Trade Size Avg Trade Size (Sh.): 131 Avg Trade Size (Sh.) (30 D): 59 Avg Trade Size (Sh.) (90 D): 64 Institutional Trades Total Inst.Trades: 8,782 Avg Inst. Trade: $3.57M Avg Inst. Trade (30 D): $8.82M Avg Inst. Trade (90 D): $10.4M Avg Inst. Trade Volume: .09M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $6.86M Avg Closing Trade (30 D): $38.62M Avg Closing Trade (90 D): $46.3M Avg Closing Volume: 166.68K     News Aug 25, 2025 @ 7:00 PM Non-cystic Fibrosis Bronchiectasis Market Ready to... Source: Delveinsight Aug 14, 2025 @ 5:00 PM Pulmonary Hypertension associated with Interstitia... Source: Delveinsight Jun 20, 2025 @ 5:37 PM Russell Rebalance: 3 Stocks Ready to Move Higher Source: Marketbeat.Com Jun 11, 2025 @ 5:32 PM Insmed's Pulmonary Hypertension Drug Data Exceeded... Source: Vandana Singh May 23, 2025 @ 8:49 AM 8MM Bronchiectasis Market Opportunity Assessment a... Source: Researchandmarkets.Com Financials   TTM Q2 2025 Q1 2025 Basic EPS $-5.69 $-1.7 $-1.42 Diluted EPS $-5.69 $-1.7 $-1.42 Revenue $ 398.11M $ 107.42M $ 92.82M Gross Profit $ 301.43M $ 79.34M $ 71.55M Net Income / Loss $ -1034.34M $ -321.69M $ -256.58M Operating Income / Loss $ -1004.86M $ -312.88M $ -248.14M Cost of Revenue $ 96.67M $ 28.08M $ 21.28M Net Cash Flow $ 37.53M $ 881.08M $ -151.78M PE Ratio     Splits Mar 03, 2011:   1:10 Jul 31, 2000:   1:4